TSX runs higher on rate cut expectations
Akero Therapeutics (NASDAQ:AKRO) Chief Scientific Officer Timothy Rolph sold 12,500 shares of common stock on August 5, 2025, for a total of $616,299. The sales were executed in two transactions at prices ranging from $49.065 to $49.494. The stock has shown remarkable strength, gaining over 122% in the past year according to InvestingPro data, with the current share price near $52.79.
Rolph also exercised options to acquire 12,500 shares of Akero Therapeutics stock at a price of $21.09, for a total value of $263625.
Following these transactions, Rolph directly owns 167,124 shares of Akero Therapeutics.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan.
In other recent news, Akero Therapeutics has been the focus of multiple analyst reports and developments. Morgan Stanley (NYSE:MS) reiterated its Overweight rating for Akero, emphasizing the company’s strengthened position following Novo Nordisk (NYSE:NVO)’s decision to halt the development of its MASH treatment, zalfermin. TD Cowen initiated coverage on Akero with a Buy rating, citing the promising clinical profile of its FGF21 analog, efruxifermin, which could drive commercial success in treating MASH. Jefferies maintained a Buy rating with a $75.00 price target, highlighting compelling data from Akero’s recent presentation at the European Association for the Study of the Liver. This data, published in The New England Journal of Medicine, showcased positive results from a placebo-controlled study on F4 cirrhosis.
Citi analysts adjusted their outlook by lowering the price target from $80.00 to $78.00 while maintaining a Buy rating, following the release of Akero’s Phase 2b SYMMETRY trial data. The trial showed positive effects on liver fibrosis metrics, further supported by earlier 96-week topline liver biopsy data. Analysts see a substantial market opportunity for Akero, with Jefferies estimating a potential range of $2 billion to $5 billion based on treating 50,000 to 100,000 patients. These developments reflect Akero’s ongoing efforts and potential in advancing its therapeutic offerings in the MASH treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.